Ulusan, Ahmet M Rajendran, Praveen Dashwood, Wan Mohaiza Yavuz, Omer F Kapoor, Sabeeta Gustafson, Trace A Savage, Michelle I Brown, Powel H Sei, Shizuko Mohammed, Altaf
...
A clinical trial in patients with familial adenomatous polyposis (FAP) demonstrated that sulindac plus erlotinib (SUL+ERL) had good efficacy in the duodenum and colon, but toxicity issues raised concerns for long-term prevention. We performed a biomarker study in the polyposis in rat colon (Pirc) model, observing phosphorylated Erk inhibition in co...
Ellingson, Benjamin M Brown, Matthew S Boxerman, Jerrold L Gerstner, Elizabeth R Kaufmann, Timothy J Cole, Patricia E Bacha, Jeffrey A Leung, David Barone, Amy Colman, Howard
...
Determination of therapeutic benefit in intracranial tumors is intimately dependent on serial assessment of radiographic images. The Response Assessment in Neuro-Oncology (RANO) criteria were established in 2010 to provide an updated framework to better characterize tumor response to contemporary treatments. Since this initial update a number of RA...
Moschopoulou, E Deane, J Duncan, M Ismail, SA Moriarty, S Sarker, S-J White, P Korszun, A
Purpose The aim of this study was to identify the most appropriate measure of quality of life (QoL) for patients living with and beyond cancer. Methods One hundred eighty-two people attending cancer clinics in Central London at various stages post-treatment, completed a series of QoL measures: FACT-G, EORTC QLQ-C30 , IOCv2 (positive and negative su...
Jayasekara, H MacInnis, RJ Lujan-Barroso, L Mayen-Chacon, A-L Cross, AJ Wallner, B Palli, D Ricceri, F Pala, V Panico, S
...
Johnson, Nichola Maguire, Sarah Morra, Anna Kapoor, Pooja Middha Tomczyk, Katarzyna Jones, Michael E Schoemaker, Minouk J Gilham, Clare Bolla, Manjeet K Wang, Qin
...
BackgroundEpidemiological studies provide strong evidence for a role of endogenous sex hormones in the aetiology of breast cancer. The aim of this analysis was to identify genetic variants that are associated with urinary sex-hormone levels and breast cancer risk.MethodsWe carried out a genome-wide association study of urinary oestrone-3-glucuronid...
Hong, Sanghee Brazauskas, Ruta Hebert, Kyle M Ganguly, Siddhartha Abdel‐Azim, Hisham Diaz, Miguel Angel Beattie, Sara Ciurea, Stefan O Szwajcer, David Badawy, Sherif M
...
BackgroundThe association of community factors and outcomes after hematopoietic cell transplantation (HCT) has not been comprehensively described. Using the County Health Rankings and Roadmaps (CHRR) and the Center for International Blood and Marrow Transplant Research (CIBMTR), this study evaluated the impact of community health status on allogene...
Andreassen, Maren M Sjaastad Rodríguez-Soto, Ana E Conlin, Christopher C Vidić, Igor Seibert, Tyler M Wallace, Anne M Zare, Somaye Kuperman, Joshua Abudu, Boya Ahn, Grace S
...
PurposeDiffusion-weighted MRI (DW-MRI) is a contrast-free modality that has demonstrated ability to discriminate between predefined benign and malignant breast lesions. However, how well DW-MRI discriminates cancer from all other breast tissue voxels in a clinical setting is unknown. Here we explore the voxelwise ability to distinguish cancer from ...
Nayak, Lakshmi Molinaro, Annette M Peters, Katherine Clarke, Jennifer L Jordan, Justin T de Groot, John Nghiemphu, Leia Kaley, Thomas Colman, Howard McCluskey, Christine
...
PurposeVEGF is upregulated in glioblastoma and may contribute to immunosuppression. We performed a phase II study of pembrolizumab alone or with bevacizumab in recurrent glioblastoma.Patients and methodsEighty bevacizumab-naïve patients with recurrent glioblastoma were randomized to pembrolizumab with bevacizumab (cohort A, n = 50) or pembrolizumab...
Fontaine, Shaun D Ashley, Gary W Houghton, Peter J Kurmasheva, Raushan T Diolaiti, Morgan Ashworth, Alan Peer, Cody J Nguyen, Ryan Figg, William D Beckford-Vera, Denis R
...
PARP inhibitors are approved for treatment of cancers with BRCA1 or BRCA2 defects. In this study, we prepared and characterized a very long-acting PARP inhibitor. Synthesis of a macromolecular prodrug of talazoparib (TLZ) was achieved by covalent conjugation to a PEG40kDa carrier via a β-eliminative releasable linker. A single injection of the PEG∼...
Garon, Edward B
Both osimertinib and the combination of erlotinib plus ramucirumab are approved for initial therapy of advanced EGFR mutation-positive non-small cell lung cancer. Osimertinib is also approved in previously treated T790M mutation-positive patients. The accompanying article reports on a study combining osimertinib with ramucirumab.See related article...